Journal of Multiple Sclerosis

Department of Physiology, Massachusetts Institute of Medical Science, Massachusetts, USA

Publications

• Perspective   
  Unlocking the Pivotal Role of Ocrelizumab in Transforming Multiple Sclerosis Treatment
  Author(s): Martin Baum* and Richard Glenn
  
  This article delves into the transformative impact of Ocrelizumab, the sole approved disease-modifying therapy for both relapsing and primary progressive forms of Multiple Sclerosis (MS). Recognized by regulatory authorities, Ocrelizumab's approval marks a pivotal shift, offering a unified therapeutic approach for a broader spectrum of MS patients. The study highlights its efficacy in reducing disability progression and suppressing relapse rates, significantly improving overall quality of life. As we celebrate these strides, the imperative for ongoing research is underscored, emphasizing the need for comprehensive, real-world data to inform treatment decisions and optimize care strategies for diverse MS patient profiles. Ocrelizumab's unique mechanism of action, targeting CD20- positive B cells, navigates the immunological landscape of MS, offering a more targeted and precise .. View More»
  DOI: 10.35248/2376-0389.24.11.1.539.

  Abstract HTML PDF